Adenosomes

Patent metadata

Field	Value
Publication number	US-12435110-B2
Application number	US-201917274891-A
Country	US
Kind code	B2
Filing date	Sep 17, 2019
Priority date	Sep 17, 2018
Publication date	Oct 7, 2025
Grant date	Oct 7, 2025

Abstract

The invention relates to a recombinant adenovirus nucleic acid wherein the gene encoding protein V and/or the gene encoding protein VII is placed under control of a heterologous promoter, to a recombinant adenovirus nucleic acid wherein the adenoviral nucleotide sequence is mutated in such a way that it is no longer capable of producing one or more of the coat proteins, to cellular vesicles filled with such adenoviral material, cells provided with such adenoviral material and to methods and use thereof.

First claim

The invention claimed is:

1. Cellular vesicle comprising a recombinant adenoviral nucleic acid, wherein the recombinant adenoviral nucleic acid comprises a mutation in the early genes, wherein the gene encoding protein V and/or the gene encoding protein VII is placed under control of a heterologous promoter.

2. Cellular vesicle comprising a recombinant adenoviral nucleic acid wherein the gene encoding protein V and/or the gene encoding protein VII is placed under control of a heterologous promoter.

3. Cellular vesicle according to claim 2 , further comprising a heterologous gene.

4. Cellular vesicle according to claim 2 , further comprising an adenoviral nucleic acid comprising a mutation in the early genes.

5. Cellular vesicle according to claim 3 , comprising
a nucleic acid molecule comprising said recombinant adenoviral nucleic acid, wherein the gene encoding protein V and/or the gene encoding protein VII is placed under control of a heterologous promoter and said heterologous gene; or
a nucleic acid molecule comprising said recombinant adenoviral nucleic acid, wherein the gene encoding protein V and/or the gene encoding protein VII is placed under control of a heterologous promoter and a nucleic acid molecule comprising said heterologous gene.

6. Cellular vesicle comprising:
i. a nucleic acid molecule comprising a recombinant adenoviral nucleic acid wherein the gene encoding protein V and/or the gene encoding protein VII is placed under control of a heterologous promoter and wherein said nucleic acid does not comprise adenoviral nucleic acid other than the genes encoding protein V and/or protein VII, and a recombinant adenoviral nucleic acid comprising a mutation in the early genes, and optionally a heterologous gene, or
ii. a recombinant adenoviral nucleic acid wherein the gene encoding protein V and/or the gene encoding protein VII is placed under control of a heterologous promoter, wherein protein V and/or protein VII is fused with a heterologous molecule, and wherein said nucleic acid does not comprise adenoviral nucleic acid other than the genes encoding protein V and/or protein VII, or
iii. adenoviral protein V and/or protein VII, wherein protein V and/or protein VII is fused with a heterologous molecule, and a recombinant adenoviral nucleic acid comprising a mutation in the early genes, wherein the recombinant adenoviral nucleic acid is an adenoviral nucleic acid of a conditionally replicating adenovirus and/or a replication-deficient adenovirus vector, or
iv. adenoviral protein V and/or protein VII wherein protein V and/or protein VII is fused with a heterologous molecule.

7. Cellular vesicle according to claim 2 , wherein the adenoviral nucleic acid wherein the gene encoding protein V and/or the gene encoding protein VII is placed under control of a heterologous promoter does not comprise adenoviral nucleic acid other than the genes encoding protein V and/or protein VII.

8. Cellular vesicles according to claim 1 wherein the vesicle is an extracellular vesicle.

9. Cellular vesicles according to claim 2 wherein the vesicle is an extracellular vesicle.

10. Cellular vesicles according to claim 6 wherein the vesicle is an extracellular vesicle.

11. A method for preparing a cellular vesicle according to claim 1 , comprising
culturing cells in a medium;
introducing a recombinant adenoviral nucleic acid into the cells, wherein the recombinant adenoviral nucleic acid comprises a mutation in the early genes, wherein the gene encoding protein V and/or the gene encoding protein VII is placed under control of a heterologous promoter; and
harvesting the cellular vesicle.

12. A method for preparing a cellular vesicle according to claim 6 , comprising
culturing cells in a medium;
introducing into the cells:

i. a nucleic acid molecule comprising a recombinant adenoviral nucleic acid wherein the gene encoding protein V and/or the gene encoding protein VII is placed under control of a heterologous promoter and wherein said nucleic acid does not comprise adenoviral nucleic acid other than the genes encoding protein V and/or protein VII, and a recombinant adenoviral nucleic acid comprising a mutation in the early genes, and optionally a heterologous gene, or
ii. a recombinant adenoviral nucleic acid wherein the gene encoding protein V and/or the gene encoding protein VII is placed under control of a heterologous promoter, wherein protein V and/or protein VII is fused with a heterologous molecule, and wherein said nucleic acid does not comprise adenoviral nucleic acid other than the genes encoding protein V and/or protein VII, or
iii. adenoviral protein V and/or protein VII, wherein protein V and/or protein VII is fused with a heterologous molecule, and a recombinant adenoviral nucleic acid comprising a mutation in the early genes, wherein the recombinant adenoviral nucleic acid is an adenoviral nucleic acid of a conditionally replicating adenovirus and/or a replication-deficient adenovirus vector, or
iv. adenoviral protein V and/or protein VII wherein protein V and/or protein VII is fused with a heterologous molecule; and
harvesting the cellular vesicle.

13. A method of treating a disease selected from the group consisting of genetic disorders, cancer or aging diseases, comprising administrating a cellular vesicle according to claim 5 to a subject in need thereof.

14. A method of treating a disease selected from the group consisting of genetic disorders, cancer or aging diseases, comprising administrating a cellular vesicle according to claim 10 to a subject in need thereof.

Assignees

• Univ Erasmus Med Ct Rotterdam

Inventors

• De Vrij Jeroen

Classifications

• C12N2810/405

  Vectors comprising RGD peptide · CPC title

• C12N2710/10362

  by genetic engineering · CPC title

• C12N2710/10345

  Special targeting system for viral vectors · CPC title

• C12N2710/10343

  viral genome or elements thereof as genetic vector · CPC title

• C12N2710/10332

  Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title